Shanghai Meiye Biotechnology

Shanghai Meiye Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative metabolic and endocrine therapies. The company specializes in the discovery of small molecule and peptide-based treatments for prevalent conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging advanced drug design and optimization techniques, Meiye Biotechnology aims to provide more effective and convenient therapeutic options for patients with metabolic disorders. The company is currently advancing several candidates through the pre-clinical stage, targeting well-validated pathways like the GLP-1 and GIP receptors.